The bill tightens export controls on digital synthetic DNA/RNA to reduce misuse and protect IP—strengthening national security and safety—but does so at the cost of new licensing and compliance burdens that will slow collaboration, raise costs for researchers and institutions, and may increase prices or delay biotech services for consumers.
Taxpayers and the general public: restricting transfers of novel synthetic DNA/RNA sequences to foreign entities of concern reduces the risk that adversaries gain capabilities that threaten U.S. security.
The public: limiting uncontrolled access to sensitive digital genetic designs lowers the chance those designs could be used to create biological threats, improving public health safety.
Scientists, researchers, and biotech firms: restricting exports of sequence data helps protect intellectual property and reduce the risk of theft of proprietary designs.
Scientists, biotech firms, and tech workers: new licensing requirements and export controls will create administrative burdens and costs that slow collaborations and delay research and product development.
Researchers, students, and public-health scientists: tighter controls on sharing digital sequences with foreign academics and companies will hinder legitimate international collaboration and slow scientific and public-health progress.
Universities, financial institutions, and other intermediaries: expanded export controls increase compliance costs and administrative burdens and, combined with ambiguities, create enforcement uncertainty.
Based on analysis of 3 sections of legislative text.
Requires licenses (within 1 year) for exports, reexports, or in‑country transfers of digital sequences of synthetic DNA/RNA to foreign entities of concern under export-control law.
Requires a federal export license, within one year, for exports, reexports, or in‑country transfers of any digital sequence of synthetic DNA or RNA to foreign entities of concern; defines covered terms and ties the new rule into existing export control law. It also expresses Congress’s view that the PRC engages in systematic efforts to acquire U.S. biological IP and that controlling digital genetic sequence exports will protect national security and U.S. biotechnology research. The bill inserts a new statutory licensing requirement into the Export Control Reform Act, narrows applicability by referring to existing regulatory exclusions, and defines ‘‘foreign entity of concern’’ and ‘‘synthetic DNA or RNA’’ for enforcement and licensing purposes.
Official title: Restrict the export to foreign entities of concern of United States intellectual property and sensitive information related to synthetic biology, and for other purposes.
Introduced December 11, 2025 by Thomas Bryant Cotton · Last progress December 11, 2025